Open

EoE Study with Dupixent

The purpose of this study is to learn whether Dupixent (dupilumab) can help with the esophagus's function in adults with eosinophilic esophagitis.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

At each visit, you will meet the study team at UNC's campus to receive the study drug or placebo injection. The assessments needed at each visit vary, but generally consist of: blood draws, physical exams, urine samples, ECG, vital signs, and questionnaires. There will also be study endoscopies and EndoFLIP procedures.

Incentives

Information provided upon request

In-person visits:
10-17

Total length of participation:
2.5 years

Looking for Specific Volunteers

Able to participate:

Eosinophilic esophagitis

Not eligible if:

Other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Active Helicobacter pylori infection

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Evan Dellon
Center for Gastrointestinal Biology and Disease

Study Type

Clinical or Medical
Interventional

Study Topics

Allergy
Chronic Conditions
Stomach, Digestion and Gut Health
Rare Diseases

IRB Number

23-1878

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.